The 13 references in paper I. Yavelov S., И. Явелов С. (2016) “ЭФФЕКТИВНОСТЬ И БЕЗОПАСНОСТЬ ПЕРОРАЛЬНЫХ АНТИКОАГУЛЯНТОВ ПРЯМОГО ДЕЙСТВИЯ В ПРОФИЛАКТИКЕ ИНСУЛЬТА У БОЛЬНЫХ С НЕКЛАПАННОЙ ФИБРИЛЛЯЦИЕЙ ПРЕДСЕРДИЙ В ПОВСЕДНЕВНОЙ КЛИНИЧЕСКОЙ ПРАКТИКЕ: ФАКТЫ О РИВАРОКСАБАНЕ // EFFICACY AND SAFETY OF DIRECT ORAL ANTICOAGULANTS IN THE PREVENTION OF STROKE IN PATIENTS WITH NONVALVULAR ATRIAL FIBRILLATION IN EVERYDAY CLINICAL PRACTICE: FACTS ABOUT RIVAROXABAN” / spz:neicon:aterotromboz:y:2016:i:1:p:69-80

1
Patel MR, Mahaffey KW, Garg J et al., for the ROCKETAF Investigators. Rivaroxaban versus warfarin in nonvalvularatrial fibrillation. N Engl J Med,2011, 365: 883-891.
(check this in PDF content)
2
Granger CB, Alexander JH, McMurray JJ et al., for the ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med, 2011, 365: 981-992.
(check this in PDF content)
3
Connolly SJ, Connolly SJ, Ezekowitz MD et al for the RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med, 2009, 361: 1139-1351.
(check this in PDF content)
4
Nguyen E, White CM, Patel MR, Fields LE, Peacock WF, Crivera C, Coleman CI. Doses of Apixaban and Rivaroxaban Prescribed in Real-World United States Cardiology Practices Compared to Registration Trials. Current Medical Research and Opinion, 2016. Doi: 10.1185/03007995.2016.1170672.
(check this in PDF content)
5
Tamayo S, Peacock WF, Patel M, Sicignano N, Hopf KP, Fields LE, Sarich T, Wu S, Yannicelli D, Yuan Z. Characterizing Major Bleeding in Patients With Nonvalvular Atrial Fibrillation: A Pharmacovigilance Study of 27 467 Patients Taking Rivaroxaban. Clin Cardiol,2015, 38: 63-68.
(check this in PDF content)
6
Cunningham A, Stein CM, Chung CP et al. An automated database case definition for serious bleeding related to oral anticoagulant use. Pharmacoepidemiol Drug Saf, 2011, 20: 560-566.
(check this in PDF content)
7
Lamberts M, Gislason GH, Lip GY et al. Antiplatelet therapy for stable coronary artery disease in atrial fibrillation patients taking an oral anticoagulant: a nationwide cohort study. Circulation, 2014, 129: 1577-1585.
(check this in PDF content)
8
Coleman CI, Antz M, Simard E, Evers T, Bowrin K, Bonnemeier H, Cappato R. REAL-WORLD EVIDENCE OF STROKE PREVENTION IN PATIENTS WITH NONVALVULAR ATRIAL FIBRILLATION IN THE UNITED STATES: THE REVISIT-US STUDY. J Interv Cardiac Electrophysiol, 2016, 45(3): 15-48. Режим доступа: http:// rd.springer.com/article/10.1007/s10840-0160108-7/fulltext.html.
(check this in PDF content)
9
Laliberte F, Cloutier M, Nelson WW, Coleman CI, Pilon D, Olson WH et al. Realworld comparative effectiveness and safety of rivaroxaban and warfarin in nonvalvular atrial fibrillation patients. Curr Med Res Opin, 2014, 30: 1317-1325.
(check this in PDF content)
10
Nelson WW, Song X, Thomson E, Smith DM, Coleman CI, Damaraju CV et al. Medication persistence and discontinuation of rivaroxaban and dabigatran etexilate among patients with non-valvular atrial fibrillation. Curr Med Res Opin, 2015, 31: 1831-1840.
(check this in PDF content)
11
Beyer-Westendorf J, Ehlken B, Evers T. Real-world persistence and adherence to oral anticoagulation for stroke risk reduction in patients with atrial fibrillation. Europace, 2016, doi:10.1093/europace/euv421.
(check this in PDF content)
12
Hecker J, Marten S, Keller L, Helmert S, Michalski F, Werth S, Sahin K, Titt L, Beyer-Westendorf J. Effectiveness and safety of rivaroxaban therapy in daily-care patients with atrial fibrillation. Results from the Dresden NOAC Registry. Thromb Haemost, 2016, 115: http:// dx.doi.org/10.1160/TH15-10-0840.
(check this in PDF content)
13
Camm AJ, Amarenco P, Haas S, Hess S, Kirchhof P, Kuhls S, van Eickels M, Turpie AGG on behalf of the XANTUS Investigators. XANTUS: a real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibril-
(check this in PDF content)